title: Effect of 4G-beta-D-galactosylsucrose (lactosucrose) on fecal microflora in patients with chronic inflammatory bowel disease.
abstract: Metabolic interaction between the intestinal microflora and the host has been suggested to play a role in the pathogenesis of chronic inflammatory bowel disease. Elemental or low-fat, low-residual diets in patients with Crohn's disease or ulcerative colitis are reported to decrease anaerobic bacteria and to change the composition of the intestinal microflora. We examined the effect of an indigestible agent, 4G-beta-D-galactosylsucrose (lactosucrose), which is selectively utilized by intestinal Bifidobacterium, on the composition of the intestinal microflora. After the administration of lactosucrose to two patients with Crohn's disease and five patients with ulcerative colitis for 2 weeks, significant induction of the growth of Bifidobacterium was observed, and significant reduction in the population level of Bacteroidaceae was seen. Bowel movements improved in four patients. The intestinal environment, estimated by measuring fecal pH, fecal levels of short-chain fatty acids and putrid products, and the urinary secretion of indican, also improved in these patients. These results suggest that lactosucrose may be useful for patients with chronic inflammatory bowel disease.
authors.affiliation: Department of Clinical Nutrition, Kawasaki University of Medical Welfare, Kurashiki, Japan.
authors.forename: F
authors.initials: F
authors.lastname: Teramoto
authors.forename: K
authors.initials: K
authors.lastname: Rokutan
authors.forename: Y
authors.initials: Y
authors.lastname: Kawakami
authors.forename: Y
authors.initials: Y
authors.lastname: Fujimura
authors.forename: J
authors.initials: J
authors.lastname: Uchida
authors.forename: K
authors.initials: K
authors.lastname: Oku
authors.forename: M
authors.initials: M
authors.lastname: Oka
authors.forename: M
authors.initials: M
authors.lastname: Yoneyama
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001644:Bifidobacterium / Q000187:drug effects / Q000302:isolation & purification; D003093:Colitis, Ulcerative / Q000382:microbiology / Q000473:pathology; D003424:Crohn Disease / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D005243:Feces / Q000382:microbiology*; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D007413:Intestinal Mucosa / Q000187:drug effects / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D014312:Trisaccharides / Q000008:administration & dosage / Q000494:pharmacology*; D016482:Urinalysis
chemical_list: D014312:Trisaccharides; C081752:galactosucrose